Table 1 Baseline characteristics of all patients enrolled to this study
Characteristics | Total (N = 60) | CB (N = 21) | NB (N = 39) | P-value |
|---|---|---|---|---|
Age(year) | Â | Â | Â | 0.108 |
 median(range) | 63.5 (19–76) | 59 (19–76) | 65 (39–76) |  |
Sex | Â | Â | Â | 0.935 |
 male | 31 (51.7) | 11 (52.4) | 20 (51.3) |  |
 female | 29 (48.3) | 10 (47.6) | 19 (48.7) |  |
Smoking | Â | Â | Â | 0.473 |
 never | 51 (85.0) | 19 (90.5) | 32 (82.1) |  |
 ever | 9 (15.0) | 2 (9.5) | 7 (18.4) |  |
Histology | Â | Â | Â | 0.119 |
 Adeno | 56 (93.3) | 18 (85.7) | 38 (97.4) |  |
 NOS | 4 (6.7) | 3 (14.3) | 1 (2.6) |  |
Number of distant metastases | Â | Â | Â | 0.217 |
 0–1 | 35 (58.3) | 15 (71.4) | 20 (51.3) |  |
 2–3 | 21 (35.0) | 6 (28.6) | 15 (39.5) |  |
  > 3 | 4 (6.7) | 0 (0.0) | 4 (10.5) |  |
Organ metastasis | Â | Â | Â | Â |
 bone | 24 (40.0) | 8 (38.1) | 16 (41.0) | 0.825 |
 brain | 13 (21.7) | 4 (19.0) | 9 (23.1) | 1.000 |
 liver | 4 (6.7) | 0 (0.0) | 4 (10.3) | 0.287 |
EGFR mutation | Â | Â | Â | 0.609 |
 19DEL | 30 (50.0) | 10 (47.6) | 20 (51.3) |  |
 L858R | 27 (45.0) | 9 (42.9) | 18 (46.2) |  |
 G719X | 3 (5.0) | 2 (9.5) | 1 (2.6) |  |
Acquired T790M | Â | Â | Â | 0.470 |
 no | 50 (83.3) | 19 (90.5) | 31 (79.5) |  |
 yes | 10 (16.7) | 2 (9.5) | 8 (20.5) |  |
Other treatmenta | Â | Â | Â | 0.129 |
 no | 38 (63.3) | 16 (76.2) | 22 (56.4) |  |
 yes | 22 (36.7) | 5 (23.8) | 17 (43.6) |  |
PD-L1 | Â | Â | Â | 0.914 |
 not clear | 52 (86.7) | 19 (90.5) | 33 (84.6) |  |
 negative | 4 (6.7) | 1 (4.8) | 3 (7.7) |  |
 positive | 4 (6.7) | 1 (4.8) | 3 (7.7) |  |
ICI line | Â | Â | Â | 0.185 |
 2–3 | 48 (80.0) | 19 (90.5) | 29 (74.4) |  |
  >  = 4 | 12 (20.0) | 2 (9.5) | 10 (25.6) |  |
ICI drug | Â | Â | Â | 0.193 |
 pembrolizumab | 12 (20.0) | 4 (19.0) | 8 (20.5) |  |
 nivolumab | 3 (5.0) | 1 (4.8) | 2 (5.1) |  |
 camrelizumab | 7 (11.7) | 3 (14.3) | 4 (10.3) |  |
 toripalimab | 9 (15.0) | 3 (14.3) | 6 (15.9) |  |
 tislelizumab | 6 (10.0) | 2 (9.5) | 4 (10.3) |  |
 sintilimab | 8 (13.3) | 2 (9.5) | 6 (15.9) |  |
 not clear | 15 (25.0) | 6 (28.6) | 9 (23.1) |  |